Trial Profile
Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Glesatinib (Primary) ; Glesatinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors MethylGene; Mirati Therapeutics
- 02 Dec 2022 Results assessing the maximum tolerated dose (MTD), recommended phase II dose (RP2D), and safety profile of glesatinib in patients with advanced or unresectable solid tumors published in the Targeted Oncology
- 11 Feb 2019 Status changed from active, no longer recruiting to completed.
- 16 Nov 2018 Results evaluating whether high MET mutant Allele Frequency of METex14 predicts tumor response to glesatinib from 265-109 and 265-101, presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.